Small Molecule Anti-Inflammatory Compounds for Cost-Effective Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and immune disorders, such as rheumatoid arthritis and sepsis, often rely on expensive therapies like monoclonal TNF-α antibodies and NSAIDs, which have adverse effects and are not effective in advanced stages, highlighting the need for more effective and safer anti-inflammatory compounds.
Innovation Solution
Development of compounds represented by formula (I) and their compositions, which inhibit LPS-induced TNF-α production, abrogate MAP kinase and NF-κB activation, and inhibit 5-lipoxygenase activity, thereby reducing inflammatory responses and cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal TNF-α antibody is used to treat inflammatory diseases, then disease progression is controlled, but treatment cost increases significantly
Solution Approach 1:
The patent employs small molecule compounds (e.g., compounds of formula I and II) as inexpensive alternatives to expensive monoclonal antibodies. These small molecules can be synthesized cost-effectively and administered orally or via other non-invasive routes, providing sustained anti-inflammatory effects without the high manufacturing costs associated with biologic drugs.
Solution Approach 2:
The patent modifies the chemical structure parameters of known anti-inflammatory compounds to optimize their TNF-α inhibition capability. By adjusting molecular weight, functional groups, and stereochemistry, the patent achieves enhanced therapeutic efficacy at lower costs compared to monoclonal antibodies.
2Object-affected harmful factors
If NSAIDs are used to treat inflammatory diseases, then acute and chronic pain is ameliorated, but adverse effects increase including gastrointestinal irritation and bone marrow suppression
Solution Approach 1:
The patent introduces novel compounds that act as intermediaries between NSAIDs and COX enzymes. These compounds selectively inhibit COX-2 or modulate COX activity with higher specificity, reducing off-target effects on gastrointestinal prostaglandins and bone marrow function while maintaining effective pain relief and anti-inflammatory activity.
Solution Approach 2:
The patent designs compounds with selective COX-2 inhibition or tissue-specific distribution properties. By targeting inflammatory sites preferentially and sparinging gastrointestinal tissue, the compounds provide effective pain relief without the severe GI side effects characteristic of traditional NSAIDs.
3Reliability
If traditional anti-inflammatory drugs are used, then they are effective in early stages of rheumatoid arthritis, but they become ineffective in advanced stages
Solution Approach 1:
The patent develops compounds with dynamic pharmacological properties that adapt to disease progression. The compounds maintain efficacy in advanced stages by targeting multiple inflammatory pathways simultaneously (TNF-α, COX-2, LOX) and can be administered in regimens that adjust to changing disease severity, providing sustained effectiveness throughout the disease course.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit TNF-α production, reducing overwhelming inflammatory responses and associated complications, offering a safer and more effective treatment option for inflammatory and immune-related conditions.
Implementation Method 1
Following exposure to pathogens and endotoxins, intracellular signaling pathways including specific kinases and transcription factors are activated to induce the expression of TNF-α. The involvement of mitogen-activated protein (MAP) kinases and the nuclear factor kappa B (NF-κB) in pathogen-induced TNF-α expression are well documented
Implementation Method 2
inhibit 5-lipoxygenase activity, thereby reducing inflammatory responses and cytokine production
Data Source
Figure 1
Figure 2A~2B
Figure 2C~3
AI summary
The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity.